Xilio Therapeutics
27 hedge funds and large institutions have $32.6M invested in Xilio Therapeutics in 2026 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 7 closing their positions.
350% more capital inflows, than outflows
Capital inflows: $8.49M | Capital outflows: $1.89M
57% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 7
13% more funds holding
Funds holding: 24 → 27 (+3)
6.52% more ownership
Funds ownership: 45.3% → 51.82% (+6.5%)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OrbiMed
New York
|
+$4.95M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$1.35M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$932K |
| 4 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$458K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$217K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Caligan Partners
New York
|
-$943K |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$307K |
| 3 |
Ghisallo Capital Management
Boston,
Massachusetts
|
-$116K |
| 4 |
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
|
-$49.1K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$33.6K |
XLO Hedge Fund Activity: Q2 2026 in Review
27 of the 8,358 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q2 2026, worth a combined $32.6M — up 48% from $22M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new XLO positions and 7 closed out — a net gain of 4 holders — while 4 added to existing stakes and 4 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $4.95M. The largest seller was Caligan Partners, exiting entirely with an estimated $943K sold.
- 27 institutional investors held Xilio Therapeutics (XLO) as of Q2 2026, up from 24 in Q1 2026.
- Funds reported $32.6M of Xilio Therapeutics stock for Q2 2026, up 48% quarter-over-quarter.
- 11 funds opened new Xilio Therapeutics positions in Q2 2026 and 7 closed out, a net change of +4 holders.
- The largest Xilio Therapeutics buyer in Q2 2026 was OrbiMed, an estimated $4.95M added.
- The largest Xilio Therapeutics seller in Q2 2026 was Caligan Partners, an estimated $943K sold.
Based on aggregated 13F filings for Q2 2026.